200
Participants
Start Date
June 10, 2014
Primary Completion Date
July 15, 2016
Study Completion Date
July 15, 2016
Ranibizumab
All patients received a single initial intravitreal injection of ranibizumab 0.5 mg/0.05 ml as per Committee for Human Medicinal Products (CHMP)approval. Further injections might have been required when monitoring reveals disease activity. Disease activity, defined as reduced visual acuity and/or signs of lesion activity, was evaluated based on clinical examination (BCVA, fundus), and/or optical coherence tomography (OCT), and/or fluorescein angiography (FAG). Bilateral treatment was allowed provided at least 14 days of intercurrence.
Novartis Investigative Site, Torino
Novartis Investigative Site, Rapallo
Novartis Investigative Site, Milan
Novartis Investigative Site, Milan
Novartis Investigative Site, Milan
Novartis Investigative Site, Varese
Novartis Investigative Site, Desenzano del Garda
Novartis Investigative Site, Conegliano
Novartis Investigative Site, Udine
Novartis Investigative Site, Padua
Novartis Investigative Site, Padua
Novartis Investigative Site, Negrar
Novartis Investigative Site, Bolzano
Novartis Investigative Site, Bologna
Novartis Investigative Site, Parma
Novartis Investigative Site, Florence
Novartis Investigative Site, Siena
Novartis Investigative Site, Pisa
Novartis Investigative Site, Ancona
Novartis Investigative Site, Bari
Novartis Investigative Site, Napoli
Novartis Investigative Site, Napoli
Novartis Investigative Site, Catanzaro
Novartis Investigative Site, Palermo
Novartis Investigative Site, Catania
Novartis Investigative Site, Cagliari
Novartis Investigative Site, Terracina
Novartis Investigative Site, Perugia
Novartis Investigative Site, Roma
Novartis Investigative Site, Roma
Novartis Investigative Site, Roma
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY